MedTrace Logo

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

NCT01310985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-03-01

No results posted yet for this study

Summary

A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer

Conditions

  • Colon Rectal Cancer Duke Stage Stageval

Interventions

DRUG

Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)

Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Principal Investigators

  • Shouki Bazarbashi, M.D. · KFSH & RC

Eligibility

Min Age
14 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310985 on ClinicalTrials.gov